EMBC

Embecta Corp. (NASDAQ:EMBC) is a medical device company that specializes in diabetes care solutions, operating as the world's largest dedicated diabetes injection device manufacturer. Founded in 1924 as part of Becton, Dickinson and Company (BD), Embecta became an independent public company in April 2022 following a spin-off from its former parent. The company is headquartered in Parsippany, New Jersey, and serves diabetes patients globally through a comprehensive portfolio of injection devices and related products. Since its independence, Embecta has focused on strengthening its core diabetes injection business while exploring new growth opportunities in the evolving diabetes care market.